FATE THERAPEUTICS (F6T BE) stock market data APIs
€0.9536
0.03(3.1%)
as of March 18, 2026
Try our APIs with
free plan!
FATE THERAPEUTICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for F6T.BE.
Prev. Close
0.9536
Open
0.9839
High
0.984
Low
0.9515
52 wk Range
0.6112-1.4155
Market Cap
4 367 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get FATE THERAPEUTICS data using free add-ons & libraries
Get FATE THERAPEUTICS Fundamental Data
FATE THERAPEUTICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
FATE THERAPEUTICS News
New
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.31 per share a year ago. These figures are adjusted ...
Fate Therapeutics: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Thursday reported a loss of $32.4 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a...
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fate Therapeutics, Inc. Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge F...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
